Reports Q1 revenue $3.397M, consensus $4.4M. “We enter the second quarter with a renewed focus on our programs that we believe exhibit the greatest potential and meaningful near-term milestones,” said Steven Kelly, President and Chief Executive Officer of Carisma. “We are pleased by the continued clinical validation of our anti-HER2 CAR-M program as evidenced by the initial data from CT-0508 and are excited to shift our attention to the development of CT-0525, which we believe has the potential to significantly increase anti-tumor activity. The preclinical proof of concept data in liver fibrosis fuels our momentum to explore the potential of engineered macrophages beyond oncology. Carisma remains committed to advancing next-generation cell therapies that hold the potential to enhance treatment options for patients grappling with cancer and other serious disorders.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARM:
- Carisma Therapeutics appoints Eugene Kennedy as Chief Medical Officer
- Carisma Therapeutics initiated with a Buy at BTIG
- Carisma Therapeutics price target lowered to $9 from $11 at H.C. Wainwright
- Carisma Therapeutics’ Compliance Hurdle: Navigating Anti-Kickback and Fraud Laws in the Pharmaceutical Landscape
- Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results